Academic literature on the topic 'Xanthines – therapeutic use'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Xanthines – therapeutic use.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Xanthines – therapeutic use"
Cazzola, Mario, Luigino Calzetta, Peter J. Barnes, Gerard J. Criner, Fernando J. Martinez, Alberto Papi, and Maria Gabriella Matera. "Efficacy and safety profile of xanthines in COPD: a network meta-analysis." European Respiratory Review 27, no. 148 (May 2, 2018): 180010. http://dx.doi.org/10.1183/16000617.0010-2018.
Full textCicero, Arrigo F. G., Federica Fogacci, Masanari Kuwabara, and Claudio Borghi. "Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update." Medicina 57, no. 1 (January 10, 2021): 58. http://dx.doi.org/10.3390/medicina57010058.
Full textCicero, Arrigo F. G., Federica Fogacci, Masanari Kuwabara, and Claudio Borghi. "Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update." Medicina 57, no. 1 (January 10, 2021): 58. http://dx.doi.org/10.3390/medicina57010058.
Full textAhmad, Saeed, Ejaz Mohiuddin, Syed Muhammad Ali Shah, Muhammad Akram, Muhammad Amjad, Jaweria Nisar, Muhammad Riaz, Naveed Munir, and Ghulam Rasool. "Therapeutic Efficacy of Urinile Against Gouty Arthritis." Dose-Response 18, no. 4 (October 1, 2020): 155932582094693. http://dx.doi.org/10.1177/1559325820946934.
Full textShen, Z., C. Colton, R. Yan, E. Polvent, V. Hingorani, S. Yan, and L. T. Yeh. "POS1128 COMBINATION TREATMENT OF AR882, A NEW URAT1 INHIBITOR, AND XANTHINE OXIDASE INHIBITORS ALLOPURINOL OR FEBUXOSTAT: EFFECT ON URIC ACID, HYPOXANTHINE AND XANTHINE IN PLASMA OR SERUM AND URINE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 843.2–843. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1215.
Full textAouffen, M'hammed, Joanne Paquin, Eric De Grandpré, Réginald Nadeau, and Mircea-Alexandru Mateescu. "Deglycosylated ceruloplasmin maintains its enzymatic, antioxidant, cardioprotective, and neuronoprotective properties." Biochemistry and Cell Biology 79, no. 4 (August 1, 2001): 489–97. http://dx.doi.org/10.1139/o01-125.
Full textMunteanu, Mircea, Adrian Sturza, Adalbert Schiller, and Romulus Timar. "Endothelial Dysfunction in Diabetes – Clasic Sources of Vascular Oxidative Stress (Nadph Oxidases, Enos Uncoupling and Xanthine Oxidase)." Romanian Journal of Diabetes Nutrition and Metabolic Diseases 20, no. 2 (June 1, 2013): 149–55. http://dx.doi.org/10.2478/rjdnmd-2013-0019.
Full textMozgovaya, E., S. Bedina, A. Trofimenko, M. Mamus, S. Spitsina, and I. Zborovskaya. "AB0061 ALTERATIONS OF XANTHINE OXIDOREDUCTASE ACTIVITY IN RED BLOOD CELLS AFTER GLUCOCORTICOID TREATMENT IN RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1062.1–1062. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3168.
Full textMokra, Daniela, and Juraj Mokry. "Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?" International Journal of Molecular Sciences 22, no. 4 (February 16, 2021): 1929. http://dx.doi.org/10.3390/ijms22041929.
Full textAuberval, Nathalie, Stéphanie Dal, William Bietiger, Elodie Seyfritz, Jean Peluso, Christian Muller, Minjie Zhao, et al. "Oxidative Stress Type Influences the Properties of Antioxidants Containing Polyphenols in RINm5F Beta Cells." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/859048.
Full textDissertations / Theses on the topic "Xanthines – therapeutic use"
Duckworth, Megan Jane Medical Sciences Faculty of Medicine UNSW. "Characterisation of the xanthineguanine phosphoribosyltransferase of helicobacter pylori as a potential therapeutic target." Publisher:University of New South Wales. Medical Sciences, 2008. http://handle.unsw.edu.au/1959.4/43418.
Full text"Evaluation of xanthine oxidase inhibitory and antioxidant activities of compounds from natural sources." 2005. http://library.cuhk.edu.hk/record=b5892399.
Full textThesis submitted in: September 2004.
Thesis (M.Phil.)--Chinese University of Hong Kong, 2005.
Includes bibliographical references (leaves 142-154).
Abstracts in English and Chinese.
Abstract --- p.i
Chinese Abstract --- p.iii
Acknowledgements --- p.v
Table of Contents --- p.vi
List of Abbreviations --- p.xii
List of Figures --- p.xv
List of Tables --- p.xix
Chapter Chapter 1 --- Introduction --- p.1
Chapter 1.1 --- Reactive oxygen species --- p.1
Chapter 1.1.1 --- Intracellular sources of ROS --- p.1
Chapter 1.1.2 --- Extracellular sources of ROS --- p.2
Chapter 1.1.3 --- Superoxide anion radicals --- p.2
Chapter 1.1.4 --- Hydrogen peroxide --- p.3
Chapter 1.1.5 --- Hydroxyl radicals --- p.3
Chapter 1.1.6 --- Singlet oxygen --- p.4
Chapter 1.1.7 --- Peroxyl radicals and peroxides --- p.4
Chapter 1.1.8 --- Damage of cellular structures by ROS --- p.5
Chapter 1.2 --- Antioxidative defence in the body --- p.6
Chapter 1.2.1 --- Antioxidant proteins --- p.6
Chapter 1.2.2 --- Antioxidant enzymes --- p.6
Chapter 1.2.3 --- Antioxidant compounds --- p.7
Chapter 1.2.3.1 --- Vitamin E --- p.8
Chapter 1.2.3.2 --- Vitamin C --- p.9
Chapter 1.2.3.3 --- Glutathione --- p.9
Chapter 1.2.3.4 --- Urate --- p.9
Chapter 1.2.3.4.1 --- Purine metabolism --- p.10
Chapter 1.2.3.4.2 --- Xanthine oxidase --- p.12
Chapter 1.2.4 --- Oxidative stress and antioxidant defence mechanisms in RBC --- p.12
Chapter 1.2.5 --- Oxidative stress and antioxidant defence mechanisms in LDL --- p.16
Chapter 1.3 --- Human diseases originated from pro-oxidant conditions --- p.16
Chapter 1.3.1 --- Atherosclerosis --- p.17
Chapter 1.3.2 --- Ischemia /reperfusion injury --- p.17
Chapter 1.3.3 --- Glucose-6-phosphate dehydrogenase deficiency --- p.18
Chapter 1.3.4 --- DNA mutation --- p.18
Chapter 1.3.5 --- Other pro-oxidant state related diseases --- p.19
Chapter 1.4 --- Hyperuricemia and gout: diseases originated from an extreme antioxidant condition --- p.19
Chapter 1.4.1 --- Inhibition of XOD as a treatment method for hyperuricemia --- p.20
Chapter 1.4.2 --- Relationship between ROS injury and hyperuricemia --- p.22
Chapter 1.5 --- Antioxidants in human nutrition --- p.23
Chapter 1.6 --- Chinese medicinal therapeutics --- p.23
Chapter 1.6.1 --- Rhubarb --- p.25
Chapter 1.6.2 --- Aloe --- p.26
Chapter 1.6.3 --- Ginger --- p.27
Chapter 1.6.4 --- Objectives of the project --- p.30
Chapter 1.6.5 --- Strategies applied to achieve the objectives of the present project --- p.30
Chapter Chapter 2 --- Materials and methods --- p.31
Chapter 2.1 --- XOD inhibition assay --- p.31
Chapter 2.1.1 --- Assay development --- p.31
Chapter 2.1.2 --- Dose-dependent study --- p.32
Chapter 2.1.3 --- Reversibility of the enzyme inhibition --- p.32
Chapter 2.1.4 --- Lineweaver-Burk plots --- p.33
Chapter 2.2 --- Lipid peroxidation inhibition assay of mouse liver microsomes --- p.34
Chapter 2.2.1 --- Preparation of mouse liver microsomes --- p.34
Chapter 2.2.2 --- Basis of assay --- p.34
Chapter 2.2.3 --- Assay procedures --- p.35
Chapter 2.3 --- AAPH-induced hemolysis inhibition assay --- p.36
Chapter 2.3.1 --- Preparation of RBC --- p.36
Chapter 2.3.2 --- Basis of assay --- p.36
Chapter 2.3.3 --- Assay procedures --- p.37
Chapter 2.4 --- Lipid peroxidation inhibition assay of RBC membrane --- p.38
Chapter 2.4.1 --- Preparation of RBC membrane --- p.38
Chapter 2.4.2 --- Basis of assay --- p.39
Chapter 2.4.3 --- Assay procedures --- p.40
Chapter 2.5 --- ATPase protection assay --- p.41
Chapter 2.5.1 --- Preparation of RBC membrane --- p.41
Chapter 2.5.2 --- Preparation of malachite green (MG) reagent --- p.41
Chapter 2.5.3 --- Basis of assay --- p.41
Chapter 2.5.4 --- Assay procedures --- p.42
Chapter 2.5.5 --- Determination of ATPase activities --- p.43
Chapter 2.5.6 --- Assay buffers --- p.43
Chapter 2.6 --- Sulfhydryl group protection assay --- p.44
Chapter 2.6.1 --- Preparation of RBC membrane --- p.44
Chapter 2.6.2 --- Basis of assay --- p.45
Chapter 2.6.3 --- Assay procedures --- p.45
Chapter 2.7 --- Lipid peroxidation inhibition assay of LDL by the AAPH method --- p.46
Chapter 2.7.1 --- Basis of assay --- p.46
Chapter 2.7.2 --- Assay procedures --- p.46
Chapter 2.8 --- Lipid peroxidation inhibition assay of LDL by the hemin method --- p.47
Chapter 2.8.1 --- Basis of assay --- p.47
Chapter 2.8.2 --- Assay procedures --- p.47
Chapter 2.9 --- Protein assay --- p.48
Chapter 2.10 --- Statistical analysis --- p.48
Chapter 2.11 --- Test compounds --- p.48
Chapter Chapter 3 --- Xanthine oxidase inhibition assay: results and discussion --- p.49
Chapter 3.1 --- Introduction --- p.49
Chapter 3.2 --- Results --- p.54
Chapter 3.3 --- Discussion --- p.59
Chapter Chapter 4 --- Lipid peroxidation inhibition in mouse liver microsomes: results and discussion --- p.64
Chapter 4.1 --- Introduction --- p.64
Chapter 4.2 --- Results --- p.64
Chapter 4.3 --- Discussion --- p.69
Chapter Chapter 5 --- Assays on protection of RBC from oxidative damage: results and discussion --- p.71
Chapter 5.1 --- Introduction --- p.71
Chapter 5.2 --- Results --- p.75
Chapter 5.2.1 --- AAPH-induced hemolysis inhibition assay --- p.75
Chapter 5.2.2 --- Lipid peroxidation inhibition assay of RBC membranes --- p.82
Chapter 5.2.3 --- Ca2+-ATPase protection assay --- p.88
Chapter 5.2.4 --- Na+/K+-ATPase protection assay --- p.95
Chapter 5.2.5 --- Sulfhydryl group protection assay --- p.100
Chapter 5.3 --- Discussion --- p.110
Chapter 5.3.1 --- AAPH-induced hemolysis inhibition assay --- p.110
Chapter 5.3.2 --- Lipid peroxidation inhibition assay of RBC membranes --- p.111
Chapter 5.3.3 --- Ca2+-ATPase protection assay --- p.113
Chapter 5.3.4 --- Na+/K+-ATPase protection assay --- p.114
Chapter 5.3.5 --- Sulfhydryl group protection assay --- p.115
Chapter 5.3.6 --- Chapter summary --- p.117
Chapter Chapter 6 --- Lipid peroxidation inhibition assay of LDL: results and discussion --- p.118
Chapter 6.1 --- Introduction --- p.118
Chapter 6.2 --- Results --- p.118
Chapter 6.3 --- Discussion --- p.134
Chapter Chapter 7 --- General discussion --- p.137
References --- p.142
Books on the topic "Xanthines – therapeutic use"
1946-, Barnes Peter J., ed. The Mechanism of action of Xanthines in respiratory disease. London: Royal Society of Medicine Services, 1988.
Find full text(Editor), K. E. Andersson, and C.G.A. Persson (Editor), eds. Anti-asthma Xanthines and Adenosine (Current clinical practice series). Elsevier, 1986.
Find full textKarl-Erik, Andersson, Persson C. G. A, and AB Draco, eds. Anti-asthma xanthines and adenosine: Proceedings of a symposium in Copenhagen, February 22-23, 1985. Amsterdam: Excerpta Medica, 1985.
Find full text1944-, Costello J. F., Piper Priscilla J, and Royal Society of Medicine (Great Britain). Respiratory Section., eds. Methylxanthines and phosphodiesterase inhibitors in the treatment of airways disease: The proceedings of a meeting held by the Respiratory Section of the Royal Society of Medicine, London, November 1993. London: Parthenon Pub. Group, 1994.
Find full text